Drug intelligence / Profile preview

MARCKS ED peptide

Development stage: Preclinical
Modality: Peptides
Administration: Intravenous

Overview

MED2 is a cell-penetrating peptide mimetic derived from the phospholipid binding domain of Myristoylated alanine-rich C-kinase substrate (MARCKS). It is being developed as a novel therapeutic for glioblastoma (GBM), an aggressive malignancy. MED2 selectively triggers cytolytic death in GBM cells by targeting the plasma membrane and inducing intracellular calcium accumulation. This mechanism allows it to overcome traditional GBM resistance mechanisms, including caspase inhibition, while sparing normal human astrocytes.

Other names: cell permeable MARCKS effector domain (ED) peptidesMARCKS ED peptide therapeutics

Targets

PS (Phosphatidylserine)

Beyond the preview

Go deeper on MARCKS ED peptide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MARCKS ED peptide.

Explore the full profile